Key result
Combined FFP, protein C concentrate, and anticoagulation yield partial control despite recurrent thrombosis and anaphylaxis.
Why the study?
Protein C deficiency is a rare autosomal recessive disorder associated with a high risk of thromboembolic complications, presenting significant management challenges.
Population
A 23-year-old woman with severe homozygous protein C type 1 deficiency
Comparison
Management with FFP, protein C concentrate, warfarin, and heparin
Design
Case report
Authors
Loading...
Current regimens yield only partial control with recurrent thrombosis and anaphylaxis; leaves open need for safer, more effective therapies in severe protein C deficiency.
Case Report (n=1)
This case highlights the significant ongoing challenges, including recurrent thrombosis and anaphylaxis, in managing severe homozygous protein C deficiency with current therapies.
Almatter et al. (2024) conducted a case report in Severe homozygous protein C type 1 deficiency (n=1). Fresh frozen plasma (FFP), protein C concentrate, warfarin, and heparin was evaluated. Management of severe homozygous protein C deficiency with FFP, protein C concentrate, warfarin, and heparin provided partial control but was complicated by recurrent thrombosis and anaphylaxis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: